Clinical trials: Chagas Disease
Chagas Disease
A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
This is a study to compare the efficacy of oral posaconazole to placebo for the treatment of asymptomatic Chagas disease. The primary hypothesis of the study is that posaconazole 400 mg twice daily improves therapeutic response…
- Trial name
- STOP CHAGAS (NCT01377480)
- Testing
- Posaconazole, Benznidazole
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Chagas Disease, Chagas Cardiomyopathy
Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children
Chagas disease (CD) could be acquired by contact with the vector, transplacentally and by blood transfusion. The duration and clinical presentation of the initial acute phase of the infection may be variable, but the majority of…
- Trial name
- NCT04090489
- Where
- Argentina
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires
Chagas' Disease
Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
The researchers in this trial want to analyze prerecorded patient data which provide information on benefits of the drug nifurtimox in patients with a sudden (acute) and long lasting (chronic) Chagas´ disease an illness caused by…
- Trial name
- NCT03784391
- Testing
- Lampit (Nifurtimox, BAYA2502)
- Where
- Argentina
- Volunteers
- 3,000 people
- Sponsor
- Bayer
Chronic Chagas Disease
Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease
Chagas Disease, caused by the parasite Trypanosoma cruzi afflicts 7 million people in Latin America, and due to migration, abroad. The diagnosis lies in clinical suspicion and serologic detection of antibodies.
- Trial name
- ATOCHA (NCT04984616)
- Testing
- 40 mg Atorvastatin/day for 120 days P.O., Atorvastatin 80
- Where
- 4 sites in Chile
- Volunteers
- 300 people
- Sponsor
- Juan D. Maya
Chagas Disease, Trypanosomiasis
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's…
- Conditions
- Chagas Disease, Trypanosomiasis, Heart Disease
- Trial name
- BENEFIT (NCT00123916)
- Testing
- Benznidazole
- Where
- 47 sites in Argentina, Bolivia and 3 more
- Volunteers
- 2,854 people, healthy volunteers welcome
- Sponsor
- Population Health Research Institute
Infectious Diseases
Sensitivity Study of Diagnostic for Detection of Chagas Infection
This study is a multi-site trial assessing the sensitivity of Chagas Detect™ Plus rapid test versus standard reference tests (e.g. IFA, IHA, RIPA) for Chagas diagnosis.
- Trial name
- NCT02134548
- Where
- 2 sites in Bolivia, Chile
- Volunteers
- 1,601 people
- Sponsor
- InBios International, Inc.
Chagas' Disease (Chronic) With Other Organ Involvement
Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation
Chagas disease is one of the most neglected vector-borne infectious disease worldwide. The first decades following the discovery of the pathology drove an international research enthusiasm, mainly concentrated on understanding…
- Trial name
- NCT03189056
- Testing
- Chagas serology, Creatinina, Urodynamic exploration
- Where
- Bolivia
- Volunteers
- 152 people
- Sponsor
- Institut de Recherche pour le Developpement